# Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions

> **NCT06987773** · PHASE1 · COMPLETED · sponsor: **APR Applied Pharma Research s.a.** · enrollment: 42 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** RLF-OD032 100 mg/mL oral suspension
- **DRUG:** Kuvan 100 MG Powder for Oral Solution

## Key facts

- **NCT ID:** NCT06987773
- **Lead sponsor:** APR Applied Pharma Research s.a.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-20
- **Primary completion:** 2025-08-29
- **Final completion:** 2025-10-28
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987773, "Study on Sapropterin Dihydrochloride Oral Suspension in Healthy Subjects Under Fed Conditions". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT06987773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*